Aldeyra Therapeutics ($ALDX): Company Moves To Appeal The Reproxalap CRL, Funded Into 2029

01 Bull Case

September 29, 2026 update. The bull case now runs through the appeal: if the Office of New Drugs accepts Aldeyra’s reading of the clinical package, reproxalap could regain value without a new trial, and the runway into 2029 gives time to pursue it. Company release

The appeal succeeds

If the Office of New Drugs sides with Aldeyra on the existing evidence, reproxalap could regain meaningful option value without another major trial.

AbbVie optionality

The option terms are large relative to Aldeyra’s current market cap if approval becomes realistic again.

Funded into 2029

Runway guidance extended on September 29, 2026 gives the company time to pursue the appeal and advance other pipeline programs.

The constructive scenario now starts with a favourable OND assessment of the disputed evidence and a clearly defined subsequent NDA response. It does not depend on a future Type D meeting: that interaction is complete. A limited requirement for further analysis or explanation could improve visibility compared with a new pivotal trial, but filing acceptance and approval would still need separate confirmation.

The second bull argument is AbbVie. The option structure remains highly relevant if reproxalap becomes approvable. A $100 million upfront payment less option fees, potential milestones and a U.S. profit split are large relative to Aldeyra’s current market value. The market does not need AbbVie to exercise tomorrow; it needs proof that the option can become realistic again.

The third constructive factor is funding flexibility. The September 29 forecast extends operational runway into 2029 without assuming potential reproxalap licensing or product revenue. Hercules was repaid April 1, and no Jefferies ATM sales were reported through June 30. These dated facts give context to financing risk; they do not guarantee unchanged burn, no future issuance or the affordability of every possible FDA requirement. Q2 2026 Form 10-Q September 29 SEC presentation

The fourth factor is pipeline breadth, but with a revised timetable. ADX-2191 PVRL Phase 3 initiation is forecast for 2027, while the earlier Recruiting registry entry remains unreconciled. Retinitis pigmentosa, ADX-248 and ADX-246 remain development opportunities rather than demonstrated commercial substitutes. Confirmed execution and interpretable human data would be needed to create value independent of reproxalap. September 29 SEC presentation

02 Bear Case

September 29, 2026 review. Aldeyra announced an intended appeal after the Type D meeting, not an agreed resubmission package. The available announcement does not prove that the FDA has permanently closed every route based on existing data. The bear risk is an adverse appeal outcome, prolonged review or additional evidence requirements. A new trial remains possible; it is not an automatic, announced consequence of appeal denial. September 29 company release

Three CRLs

The repeated regulatory failures are not noise; they show a persistent efficacy evidence problem.

New study may be required

If FDA requires another adequate and well-controlled trial, the timeline and cost expand sharply.

Backup assets need proof

ADX-2191, ADX-248 and ADX-246 are important but still need execution, enrollment and data.

The bear case is also strong. The FDA has now rejected reproxalap three times for dry eye disease. The most recent rejection did not merely request a paperwork fix. It challenged the totality of evidence and the consistency of clinical results. That is the core problem for the stock.

The second bear argument is that management’s interpretation may not match the regulator’s interpretation. Aldeyra believes that much of the trial package supports efficacy. The FDA has repeatedly disagreed. Investors should care more about the FDA’s interpretation because FDA approval, not investor-deck logic, determines commercial access.

The third bear argument is that the AbbVie option may be less valuable than it appears if approval is not close. The headline economics are meaningful, but the option is not exercised and depends on FDA approval. Without a realistic regulatory path, the option becomes distant optionality rather than near-term value.

The fourth bear argument is that the pipeline reset is still early. ADX-2191 has rare-disease potential, but rare-disease trials can be slow and small datasets can be difficult to interpret. ADX-248 and ADX-246 remain at earlier development stages. Cash gives time, but time alone does not create clinical success.

What Would Falsify This Reading

This page reads Aldeyra as a company with money, a long regulatory history and one unresolved argument with the FDA about whether its evidence shows efficacy. Five things would show that reading to be wrong, and each is checkable against a filing or an announcement rather than an opinion.

• The Office of New Drugs decides for the company. The Formal Dispute Resolution Request is an appeal of the March 16, 2026 Complete Response Letter, with submission and an Office of New Drugs meeting expected in the fourth quarter of 2026. A decision that overturns the efficacy conclusion would change the central question of this page, though it would still be followed by a resubmission rather than by an approval.
• The the appeal submission or OND meeting does not occur in the company’s guided Q4 window. The company states that timing depends on whether the deciding official asks for more information, consults internal or external experts or convenes an advisory panel. Any of those would push the answer well beyond the fourth quarter, and a delay of that kind is not a neutral event for a company that funds itself from a fixed cash balance.
• The 2029 runway turns out to depend on assumptions that change. The guidance issued on September 29, 2026 projects operational cash into 2029 on the $45.1 million reported at June 30. It is a projection of spending, not a balance. A restart of the ADX-2191 Phase 3, a new trial demanded by the FDA, or a commercial build would consume it faster than the projection assumes.
• AbbVie moves, in either direction. The option arrangement is described in this page as optionality rather than as an asset with a value. An exercise, a renegotiation or a formal lapse would each settle a question that is currently open, and only the first of the three would be favourable.
• ADX-2191 produces a trial rather than a plan. Phase 3 initiation in primary vitreoretinal lymphoma is guided for 2027. A registered trial with sites and a first patient dosed would make the second programme real; continued silence would confirm that the company has one asset and one argument.

None of these is a prediction. They are the observations that would make the rest of this page wrong, listed so that a reader can check them rather than take the reading on trust.

03 After the September 25 Type D meeting, Aldeyra moves to a formal FDA appeal

September 29, 2026 update. This section records the Type A and Type D sequence. The Type D meeting was held on September 25, 2026, and on September 29 Aldeyra announced the intent to appeal the March 16, 2026 CRL through a Formal Dispute Resolution Request, with submission and an Office of New Drugs meeting expected in Q4 2026. Form 8-K

Aldeyra disclosed that the FDA Type A meeting on the possible reproxalap NDA resubmission was held on June 10, 2026. The company received the meeting minutes on July 14, requested clarification on July 15, and said it intended to request a Type D meeting expected by the end of Q3 2026, which was held on September 25, 2026. Aldeyra has not publicly released the substantive FDA feedback contained in the minutes, so the hub remains a regulatory-path and evidence-consistency story after the 2026 CRL, not a clean approval setup.

The Type D meeting has now occurred. Aldeyra’s September 29 announcement makes the next step explicit: an intended formal appeal to the Office of New Drugs. The company has not announced that the FDA has accepted a path without new trials. The deciding official’s assessment, any additional information requested and the requirements for a subsequent NDA resubmission remain unresolved. The meeting format itself does not establish regulatory agreement. September 29 company release September 29 SEC presentation

A separate BlackRock Schedule 13G/A filed on July 27, 2026 reported beneficial ownership of 1,045,764 shares, or 1.7%, as of June 30. This is an ownership disclosure rather than a clinical or regulatory catalyst.

04 Current Catalyst

September 29, 2026 update. The current catalyst is no longer the webcast, held on September 29 at 8:00 a.m. ET, but the formal dispute. Aldeyra expects to submit the FDRR and to meet the Office of New Drugs in the fourth quarter of 2026. The company states that the timing of the OND decision depends on whether the deciding official requests additional information, consults internal or external experts or convenes an advisory panel, and that the occurrence and timing of those steps are uncertain. No decision date has been set. Company release

FDA Type D meeting held on September 25, 2026; Aldeyra now intends to submit a Formal Dispute Resolution Request, with submission and an Office of New Drugs meeting expected in Q4 2026.

The current catalyst is the intended FDRR submission and OND meeting in Q4 2026. The earlier sequence remains relevant: Type A on June 10, minutes received July 14, clarification requested July 15 and Type D held September 25. These are completed procedural steps; they must not be described as future catalysts.

The next evidence to monitor is confirmation of actual submission, the accepted scope of the appeal, meeting arrangements and the OND response. A Q4 submission/meeting expectation does not fix the appeal decision or an approval date. Consultation with experts or an advisory panel is possible, but no advisory committee has been announced or scheduled in the September 29 materials. September 29 company release

Formal dispute resolution

Type D meeting held on September 25, 2026; FDRR submission and an Office of New Drugs meeting expected in Q4 2026.

Third CRL

FDA again cited lack of substantial evidence of efficacy and inconsistent trial results in dry eye disease.

AbbVie

AbbVie option remains contractually important, but its practical value now depends heavily on the FDA path.

Cash Runway

$45.1 million cash at June 30, 2026; on that balance the company extended its projected operational runway into 2029 on September 29, 2026, from the second half of 2028.

05 Executive Summary

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on immune-mediated diseases. The company’s scientific identity is built around reactive aldehyde species, or RASP, and the idea that certain inflammatory and metabolic disease processes can be addressed by modulating protein systems rather than directly inhibiting or activating a single target. In practical stock-market terms, however, Aldeyra has been dominated for years by one asset: reproxalap, a topical ocular RASP modulator developed for dry eye disease and allergic conjunctivitis.

The old $ALDX story was easy to describe. Reproxalap had a large commercial opportunity, a differentiated rapid-onset profile, a partnership option with AbbVie and a repeated chance to finally clear FDA review. That story has now become more complicated. The FDA has rejected the reproxalap dry eye disease NDA three times: first in 2023, then again in April 2025, and again with a Complete Response Letter dated March 16, 2026 and announced on March 17. The most recent CRL was severe on efficacy. It stated that the application lacked substantial evidence from adequate and well-controlled investigations, failed to demonstrate efficacy in signs and symptoms of dry eye disease, and that inconsistent trial results raised serious concerns about the reliability and meaningfulness of the positive findings. No safety or manufacturing issues were identified.

The current story is therefore not “reproxalap approval is around the corner.” That would be too aggressive and is not supported by the record. The Type A meeting was held on June 10, 2026, Aldeyra received the minutes on July 14 and requested clarification on July 15. In July the company said it intended to request a Type D meeting, expected by the end of Q3 2026, to discuss a potential NDA resubmission; the meeting was held on September 25, 2026, and on September 29 Aldeyra chose a formal appeal of the CRL instead of a resubmission. Because Aldeyra has not disclosed the substance of the Type A minutes, investors still do not know whether the FDA sees a viable path based on the existing evidence, a narrower issue that can be addressed in a bounded response, or a need for additional clinical work.

This creates a strange but tradable setup. The asset is damaged, but not formally dead. The FDA criticism is serious, but the agency did not identify safety or manufacturing deficiencies. Aldeyra has said the FDA did not recommend conducting additional trials or request submission of additional confirmatory evidence in the March 2026 CRL, although the company also warns that the FDA could still require additional studies, clinical trials or other work before a potential resubmission or approval. The market is therefore watching for the difference between a salvageable regulatory path and a long reset.

Aldeyra still has no approved products or commercial product revenue base. The $75 million Jefferies ATM provides potential issuance capacity, but the Q2 10-Q reports no sales under that agreement through June 30, 2026. That statement does not certify activity after that date. The current thesis is a funded regulatory appeal with further NDA work still ahead, alongside pipeline execution risk. ADX-2191 Phase 3 initiation is now guided for 2027, while the older registry entry remains unreconciled. Q2 2026 Form 10-Q September 29 SEC presentation

06 Fast Snapshot

Snapshot review: September 29, 2026. Financial balances and market observations retain the dates printed beside them. They are not live valuations.

07 Company Overview: What Aldeyra Actually Is

Aldeyra is a small biotechnology company with a broad scientific story and a narrow market narrative. The broad story is the RASP platform. Reactive aldehyde species are toxic, pro-inflammatory molecules that can arise from oxidative stress and metabolic processes. Aldeyra’s thesis is that modulating RASP can influence multiple inflammatory pathways at once, potentially creating therapeutic effects without the toxicity associated with forcing a single protein target permanently on or off.

That scientific idea is the foundation for several product candidates. Reproxalap is the late-stage topical ocular candidate for dry eye disease and allergic conjunctivitis. ADX-2191 is an intravitreal methotrexate formulation being developed for rare retinal inflammatory diseases, including primary vitreoretinal lymphoma and retinitis pigmentosa. ADX-248 and ADX-246 are next-generation RASP modulators aimed at systemic, dermatologic, metabolic, neuroinflammatory and retinal disease areas.

The stock market, however, has mostly treated Aldeyra as a reproxalap company. That is understandable. Dry eye disease is a large commercial market, reproxalap has a rapid-onset positioning argument, and AbbVie’s option agreement gave the asset external validation. But the repeated FDA rejections mean the market now has to revalue the company as something else: a post-CRL regulatory recovery story plus a funded early-to-mid-stage pipeline reset.

This is the first major interpretive shift for $ALDX. Before March 2026, the key question was whether the FDA would finally accept the totality of evidence and approve reproxalap. After March 2026, the key question is whether the FDA will allow a realistic path to approval without another major clinical trial. If yes, the stock could quickly move back toward a recovery framework. If no, then the company’s value increasingly shifts to cash, ADX-2191, ADX-248, ADX-246 and whatever remains of AbbVie optionality.

08 The Full Reproxalap FDA Timeline

September 29, 2026 update. September 25, 2026: Type D meeting with the FDA on reproxalap in dry eye disease. September 29, 2026: Aldeyra announces the intent to submit a Formal Dispute Resolution Request to the Office of New Drugs, appealing the March 16, 2026 CRL; submission and an OND meeting are expected in Q4 2026. The June 10 Type A meeting, the July 14 minutes and the July 15 clarification request are the earlier steps. Form 8-K

The $ALDX story cannot be understood without the full regulatory timeline. Reproxalap has been close enough to approval to attract strong speculative interest, but repeatedly blocked by the same core problem: FDA doubts about the strength, consistency and interpretability of the efficacy evidence in dry eye disease. Safety has not been the main issue. Manufacturing has not been the main issue. Efficacy has been the wall.

November 2022 — Original NDA submission

Aldeyra submitted the original reproxalap NDA for the treatment of signs and symptoms of dry eye disease. The application positioned reproxalap as a first-in-class RASP modulator with rapid activity and a differentiated topical ocular profile.

February 2023 — FDA acceptance and first PDUFA cycle

The FDA accepted the NDA for review and set a PDUFA target action date. At this point, the market treated reproxalap as a potentially approvable dry-eye therapy with a large addressable commercial opportunity.

November 2023 — First Complete Response Letter

The FDA declined to approve the original NDA and asked for at least one additional adequate and well-controlled study to demonstrate a positive effect on ocular symptoms of dry eye disease.

October 2024 — Resubmission

Aldeyra resubmitted the NDA after generating additional clinical data. In November 2024, the FDA accepted the resubmission and set an April 2, 2025 PDUFA date.

April 2025 — Second Complete Response Letter

The FDA again declined approval, stating that the NDA failed to demonstrate efficacy in adequate and well-controlled studies for ocular symptoms associated with dry eyes. The agency requested at least one additional adequate and well-controlled study.

May 2025 — Additional chamber trial data

Aldeyra announced that an additional dry eye chamber trial achieved the primary endpoint of reducing patient-reported ocular discomfort with P=0.002. This became the central basis for the next resubmission.

June-July 2025 — Resubmission and review acceptance

The company resubmitted the NDA in June 2025. The FDA accepted it as a complete class 2 response in July 2025 and assigned a December 16, 2025 PDUFA date.

December 2025 — Major amendment and PDUFA extension

The FDA requested the clinical study report for a dry eye field trial. Aldeyra submitted it, and the FDA treated it as a major amendment, extending the PDUFA date to March 16, 2026. The field trial was supportive of activity but did not meet its primary symptom endpoint versus vehicle.

March 16, 2026 — Third Complete Response Letter (announced March 17)

The FDA issued another CRL, citing lack of substantial evidence, failure to demonstrate efficacy in signs and symptoms of dry eye disease, and inconsistent study results that raised serious concerns about reliability and meaningfulness. No safety or manufacturing issues were identified.

May 7, 2026 — Type A meeting scheduled

Aldeyra disclosed in its Q1 2026 10-Q that it had scheduled a Type A meeting with the FDA to understand the actions needed for potential reproxalap NDA approval.

June 10, 2026 — Type A meeting held

The company later disclosed that the FDA Type A meeting regarding a possible reproxalap NDA resubmission took place on June 10.

July 14–15, 2026 — Minutes, clarification request and Type D plan

Aldeyra received the Type A meeting minutes on July 14, requested clarification on July 15 and said it intends to request a focused Type D meeting expected by the end of Q3 2026 to discuss a potential resubmission.

Why the timeline matters

Reproxalap’s history reflects repeated FDA concerns about the strength, consistency and interpretability of the evidence package. The July clarification and September Type D meeting were steps toward understanding a potential resubmission; the September 29 plan now makes formal dispute resolution the next route. The question remains whether the disputed evidence can support a workable NDA response or whether more substantial work will be required. September 29 company release September 29 SEC presentation

09 The March 2026 CRL: What the FDA Said and Why It Hurt

The third CRL was not a small delay. It was a fundamental challenge to the efficacy package. The FDA stated that the application lacked substantial evidence from adequate and well-controlled investigations and that the drug product had failed to demonstrate efficacy in adequate and well-controlled studies in the treatment of signs and symptoms of dry eye disease. The agency also pointed to inconsistency of results, saying the pattern raised serious concerns about the reliability and meaningfulness of the positive findings and that the totality of completed trials did not support effectiveness.

The damaging part is the phrase “totality of evidence.” Aldeyra’s counter-argument has long rested on the totality of data: multiple trials, multiple endpoints, rapid onset, consistent safety and a broad RASP-based biological rationale. The FDA’s latest language essentially challenged that whole framing. It did not say “fix manufacturing.” It did not say “answer one narrow safety question.” It said the efficacy evidence is not convincing enough.

The positive side is equally important. The CRL did not identify safety or manufacturing issues. Aldeyra’s May 2026 corporate overview says the FDA recommended exploring reasons for failure in certain trials and identifying populations or conditions in which reproxalap may be effective, but did not recommend conducting additional trials or request submission of additional confirmatory evidence. That distinction kept the story alive long enough for the June 10 Type A meeting. The July filing, however, disclosed only the process sequence—not the substance of the FDA minutes—and the move toward a Type D meeting does not by itself establish that the existing evidence can support a resubmission.

The Type A and Type D meetings have occurred, but the dispute over the evidence remains. The company’s statement that the latest CRL did not request additional trials does not establish that the current package is sufficient or that further studies cannot be required. The FDRR is an attempt to obtain a different assessment of that package; its existence is not evidence of FDA agreement. September 29 company release

What the September 29 evidence table actually shows

Aldeyra reports nine adequate and well-controlled trials across the submissions, five meeting all multiplicity-controlled primary endpoints; it also counts nine of fourteen primary endpoints with P values below 0.05. This is management’s case for the totality of evidence. The deck explicitly labels its summary of the FDA position as Aldeyra’s abbreviated interpretation of the review, rather than an independently published FDA assessment. September 29 SEC presentation

Merlintrader’s interpretation is that the dispute concerns the credibility, consistency and regulatory sufficiency of the evidence, not merely a count of successful P values. Aldeyra’s comparison with trial success rates of approved dry-eye drugs is an advocacy argument across different programs and designs; it does not establish equivalent efficacy or a probability of approval.

10 From the Type D Meeting to the Formal Appeal and NDA Resubmission

The September 25 Type D meeting followed the June 10 Type A end-of-review meeting and the July exchange on the minutes. On September 29 Aldeyra announced its intention to challenge the March 16 CRL through a Formal Dispute Resolution Request to the FDA’s Office of New Drugs. This escalates a scientific disagreement beyond the reviewing division. The release describes an intended filing; it does not announce that the FDRR has already been submitted or granted. September 29 company release

A Type D meeting is a focused interaction, not an approval mechanism. The September materials explain the action Aldeyra intends to take after the meetings, but do not reproduce full FDA minutes or establish that the regulator agrees with management. The earlier scenarios of a bounded response, additional analysis or substantial new clinical work remain possible branches of the regulatory problem; the formal appeal is now the process through which the company seeks to resolve it.

Appeal granted is not approval. A favourable appeal could resolve a disputed scientific point and make a resubmission more practical, but the company expressly states that the NDA must then be resubmitted with any information required by the decision. Neither the necessary review classification nor a new action date has been established. September 29 SEC presentation

FDA guidance describes 30-day response goals, including a decision or interim response after an accepted request and following a meeting. Requests for information or consultation can change the sequence and timing. These procedural goals cannot be converted into a guaranteed 30- or 60-day approval clock. An advisory panel remains a possible procedural branch, not a scheduled event. FDA dispute-resolution guidance

Scenario analysis: a favourable decision with limited additional requirements would improve regulatory visibility; a request for analyses or expert review could preserve the path while extending uncertainty; an adverse decision or substantial evidence requirement could increase cost and delay. A further trial is a risk, not an announced consequence of a denied appeal. No reliable numerical probability is assigned to these branches.

11 AbbVie Optionality: Still Important, But No Longer Simple

September 29, 2026 update. The September 29 release and Form 8-K do not announce an exercise of the AbbVie option or a new commercial commitment. The practical value of the option now depends on the outcome of the formal dispute. Form 8-K

AbbVie is one of the reasons $ALDX has remained more interesting than many post-CRL biotech names. In 2023, Aldeyra entered into an exclusive option agreement under which AbbVie could obtain a co-exclusive U.S. license to develop, manufacture and commercialize reproxalap and an exclusive license outside the United States. If the option is exercised, AbbVie would pay Aldeyra a $100 million upfront payment less previously paid option fees. Aldeyra would also be eligible for up to approximately $300 million in regulatory and commercial milestones, including a $100 million milestone connected to FDA approval, plus a U.S. profit/loss split and tiered royalties outside the U.S.

The structure became even more important in 2024 when the option framework was expanded around FDA approval timing and pre-commercial activities. The option exercise period was restricted to ten business days following FDA approval of the reproxalap NDA, if approval occurs. As of August 6, 2026, AbbVie had not exercised the option, according to the Q2 10-Q. That is not surprising because there is no FDA approval yet.

The mistake would be treating the AbbVie option as if it offsets the CRL. It does not. The option is valuable only if the regulatory path remains realistic. If the FDA leaves a manageable route, AbbVie optionality could become a powerful upside layer because the headline economics are large relative to Aldeyra’s current market capitalization. If the FDA effectively requires a new pivotal trial, AbbVie may have little reason to exercise quickly, and the market may discount the option as contingent and distant.

The formal appeal and subsequent NDA requirements now precede AbbVie in the catalyst chain. The Q2 10-Q states that the option had not been exercised as of August 6, 2026; the September 29 materials announce no exercise. The potential $100 million upfront is reduced by prior option fees, the approximately $300 million milestone maximum includes the $100 million FDA-approval milestone, and U.S. profits/losses would be split 60% to AbbVie and 40% to Aldeyra under the contemplated collaboration. These conditional amounts must not be added to present cash or counted twice. A favourable FDRR decision would not itself trigger an approval-linked payment. Q2 2026 Form 10-Q

12 Pipeline Map After the CRL

One of the most important changes after March 2026 is that Aldeyra can no longer be analyzed only through reproxalap. The dry-eye asset still dominates sentiment, but the company’s survival as a biotech story increasingly depends on whether the broader pipeline can carry value if reproxalap remains blocked.

Pipeline timing reconciled against the September 29 company presentation. Historical program descriptions are retained below with their original context; an omitted or undated milestone does not by itself establish discontinuation. September 29 SEC presentation

13 ADX-2191: The Rare Retinal Disease Backup Plan

ADX-2191 deserves more attention now than it did during the clean reproxalap PDUFA phase. It is a proprietary intravitreal formulation of methotrexate being developed for rare retinal diseases, including primary vitreoretinal lymphoma and retinitis pigmentosa. In Aldeyra’s pipeline, ADX-2191 is important because it gives the company another late-stage or potentially pivotal path that is not dependent on the dry-eye FDA debate.

In primary vitreoretinal lymphoma (PVRL), Aldeyra describes a rare, aggressive retinal malignancy, with compounded intraocular methotrexate used in clinical practice. The company has previously reported orphan designation and a Special Protocol Assessment agreement. These are development/regulatory context, not proof of trial initiation or approval. The September 29 presentation now forecasts Phase 3 initiation in 2027. September 29 SEC presentation

The registered study NCT07402876 compares cancer-cell clearance under different intravitreal methotrexate dosing regimens and lists an estimated 20 participants. At the September 29 check, ClinicalTrials.gov still displays Recruiting, an estimated February 2026 start and estimated December 2026 completion. However, its last posted update is February 11, 2026, with status verified in January. Those registry fields conflict with the much newer company forecast of initiation in 2027. They cannot establish that enrollment is currently under way or that a December 2026 readout is expected. ClinicalTrials.gov NCT07402876 September 29 SEC presentation

Retinitis pigmentosa is the other previously described ADX-2191 opportunity. Aldeyra reported an eight-patient Phase 2 study in rhodopsin-misfolding mutations, with improvements from baseline in retinal sensitivity and visual function. Earlier plans described a randomized, double-masked Phase 2/3 comparing high and low monthly doses against sham over 12 months in approximately 45 patients, with peripheral sensitivity to green, rod-mediated light under dark-adapted conditions as the primary endpoint. These are historical data and design plans, not confirmation that the proposed trial has started. The September 29 milestone slide provides no refreshed initiation date for this indication. September 29 SEC presentation

These retinal programs should not be treated as automatic rescue assets. They are still investigational and, in the case of retinitis pigmentosa, based on a very small prior dataset. But they matter because they create an alternative clinical path at a time when reproxalap has lost its clean regulatory narrative.

What remains unresolved: the company has not explained in the reviewed materials how the old Recruiting entry relates to the 2027 initiation guidance. This hub therefore uses the latest company timeline for planning, flags the registry discrepancy and assigns no current enrolled-patient count or PVRL readout date. Confirmation of trial initiation, updated registry dates and actual enrollment would be distinct future developments. Rare-disease patient identification, site readiness, recruitment speed and small-sample interpretation remain material execution risks.

14 ADX-248 and ADX-246: The Platform Reset

ADX-248 and ADX-246 are where Aldeyra’s platform story becomes more forward-looking. After the reproxalap CRLs, investors need to decide whether RASP modulation is still a valuable technology platform or whether reproxalap’s regulatory struggle weakens confidence in the whole approach. Aldeyra’s answer is to emphasize next-generation candidates.

ADX-248 is an orally administered RASP modulator. In Aldeyra’s May 2026 corporate overview, it is connected to atopic dermatitis, Sjögren-Larsson syndrome, obesity/hypertriglyceridemia, moderate alcohol-associated hepatitis and CNS/neuroinflammatory disease. The company has highlighted preclinical activity, including cytokine reduction and activity in animal models. The atopic dermatitis Phase 2 clinical trial initiation was guided for H1 2026 in the May 2026 corporate overview, while an IND for obesity/hypertriglyceridemia was guided for 2026. After H1 closed, the important editorial point is confirmation: the program remains relevant, but investors should look for a specific company update that confirms initiation or explains any delay.

ADX-246 is an intravitreal RASP modulator positioned for retinal disease, including dry age-related macular degeneration and geographic atrophy. In the May 2026 presentation, Aldeyra connected ADX-246 to retinaldehyde binding and reduction of toxic retinaldehyde metabolite A2E in an animal model. An IND submission for dry AMD/geographic atrophy was guided for 2026.

The strategic value of these programs is optionality. If reproxalap remains blocked, Aldeyra needs a way to convince investors that RASP modulation still has a future. ADX-248 and ADX-246 provide that possibility, but they are not near-term commercial assets. They are early clinical or preclinical-to-clinical transition stories. The market will need actual human data, regulatory progress and focused development plans before assigning large value.

The post-CRL pipeline reset is therefore real but not instantly bankable. It is a reason not to treat Aldeyra as a one-asset shell. It is not, by itself, enough to offset an adverse appeal outcome or a requirement for substantial new reproxalap evidence.

September 29 timing update. The current presentation says that timelines for ADX-248 in atopic dermatitis and obesity/hypertriglyceridemia, and ADX-246 in dry AMD/geographic atrophy, will be provided when available. The May H1 2026 Phase 2 and 2026 IND expectations described above are historical guidance, not verified achievements or active dated catalysts. The absence of a new date is not evidence of discontinuation. It does mean that confirmation of the next development step is needed before these programs can be placed on a dated catalyst calendar. September 29 SEC presentation

15 Financial Position: Cash Is the Biggest Stabilizer

Financial review: June 30 balance sheet, September 29 runway guidance. Aldeyra reported $45.1 million of cash and equivalents at June 30, 2026, versus $70.0 million at December 31, 2025. The September 29 release extends projected operational cash runway into 2029. This is updated planning guidance based on a dated reported balance, not a new September cash disclosure or a newly announced capital raise. Q2 2026 Form 10-Q September 29 company release

The first-half cash reconciliation is important. Cash declined by approximately $24.95 million, but only $9.70 million was operating cash consumption. The company also repaid $15.00 million of loan principal and paid a $0.30 million end-of-term charge; option proceeds and minor investing activity account for the remaining difference. The April 1 Hercules repayment and termination are already reflected in the June 30 balance, when the company reported no debt obligations. Subtracting the same debt again from June cash would understate liquidity. Q2 2026 Form 10-Q

Operating cash consumption was materially lower than the $21.02 million in the first half of 2025. The 10-Q attributes the reduction principally to lower research and development activity, lower value of stock-based cash awards and changes in accrued expenses and payment timing. A lower historical burn rate does not mean all future programs can be advanced at the same cost. Trial initiation, additional FDA work or parallel pipeline development could increase spending. The earlier first-quarter operating outflow of approximately $5.1 million remains historical context; the six-month figure is the more recent cumulative measure. Q2 2026 Form 10-Q

The September runway forecast excludes potential reproxalap licensing and product revenue and replaces the earlier second-half-2028 expectation. It should be read as funding into some point in 2029, not necessarily through December 2029. The company has not disclosed a detailed bridge explaining the extension, so it would be speculative to assign the change entirely to a specific program delay or cost cut. The forecast depends on the operating plan and does not guarantee that another major reproxalap trial would be fully funded under the same assumptions. September 29 SEC presentation

Cash therefore supports the ability to pursue the appeal and selected pipeline work, while efficacy uncertainty remains unchanged. Future funding could still be required for broader development or commercialization. The reported $37.9 million of stockholders’ equity is an accounting balance, not a valuation floor, and neither historical cash per share nor an unexercised partnership option guarantees protection against a negative regulatory outcome.

16 Dilution, ATM and Capital Structure Risk

$ALDX is not currently the same kind of dilution story as many cash-starved nano-cap biotechs, but dilution still belongs in the analysis. The company has no approved products, has funded itself historically through equity securities, convertible securities, warrants and debt facilities, and still has meaningful development obligations ahead.

In August 2024, Aldeyra entered a Jefferies ATM agreement permitting up to $75.0 million of common-stock sales. The Q2 10-Q reports no shares sold under this agreement through June 30, 2026, updating the older March reference. Available capacity is not an announced issuance, and the filing does not establish subsequent activity. A regulatory-driven rally could affect financing choices, but no new sale is inferred from the September news. Q2 2026 Form 10-Q

The runway forecast reduces near-term funding pressure under the current plan, but it does not eliminate dilution risk. A favourable appeal with limited additional work and an adverse outcome requiring substantial new evidence imply different capital needs. Capital allocation must therefore be assessed alongside the actual FDA requirements and pipeline execution, not from cash runway alone.

17 Russell Deletion and Liquidity Context

Aldeyra appeared on the June 2026 Russell 3000 deletion list. This is not a scientific or regulatory judgment. Russell index membership is driven by market capitalization, eligibility and index construction rules, not by whether a drug works. Still, the deletion is relevant because passive index flows can matter in small-cap biotech.

The 2026 Russell reconstitution took effect after the U.S. market close on June 26, with the newly reconstituted indexes operating from the open on June 29. For a name like $ALDX, deletion can reduce passive ownership, create temporary selling pressure around implementation and change the liquidity profile. After the rebalance, the useful question becomes whether the stock can absorb the flow and begin trading on company-specific catalysts again.

That timing intersected with the regulatory clarification process. The Type A meeting had already occurred by the time the June rebalance took effect, but the minutes and Type D plan were not disclosed until July. Post-rebalance trading therefore reflects a mixture of company-specific regulatory risk, small-cap liquidity and the removal of a passive-flow support source. None of those factors proves that the next FDA interaction will be favorable.

18 Management and Governance

Aldeyra is led by Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer. The company’s public communication has been unusually data-heavy around reproxalap, including repeated attempts to explain why management believes the totality of evidence supports the drug despite FDA concerns. That creates a double-edged governance issue. On one side, management has not abandoned the asset and has built a detailed argument around the trial package. On the other side, after three CRLs, investors need to ask whether management’s interpretation of the data has repeatedly diverged from the regulator’s interpretation.

The June 2026 appointment of Darlene Deptula-Hicks to the board is relevant. She brings more than 30 years of senior biotechnology leadership experience across public and private life science companies, including CFO, capital markets, strategic partnership and M&A experience. For a company at Aldeyra’s stage, that kind of profile can matter because the next phase may require financing judgment, strategic partnering discipline and careful capital allocation.

Governance should be viewed through execution. Aldeyra has cash, but cash can be burned in many ways. The company must decide how much to spend pursuing reproxalap, how aggressively to advance ADX-2191, how much capital to allocate to ADX-248 and ADX-246, and whether to seek external partnerships beyond AbbVie. The right strategy after a third CRL may not be the same as the right strategy before it.

19 Institutional Ownership Update

On July 27, 2026, BlackRock filed an amended Schedule 13G reporting beneficial ownership of 1,045,764 Aldeyra shares, equal to 1.7% of the outstanding class, as of June 30. The filing reported sole voting and dispositive power over those shares and checked the box indicating ownership of 5% or less.

The filing should be read narrowly. It is a regulatory ownership disclosure, not a statement about reproxalap, the Type D meeting or the probability of FDA acceptance. The filing also notes that it reflects securities attributed to certain BlackRock business units and excludes holdings, if any, reported separately by disaggregated business units under the cited SEC framework.

For the stock hub, the practical takeaway is that a major asset manager remains present but below the 5% threshold in the latest disclosed position. This is relevant to ownership structure and liquidity, but it does not replace a complete institutional-ownership analysis based on current 13F data, passive-fund changes and other holders’ filings.

A more recent and larger position followed on August 12, 2026, when AQR Capital Management, LLC and AQR Capital Management Holdings, LLC filed a Schedule 13G reporting beneficial ownership of 3,751,558 shares, or 6.22% of the class, as of June 30, 2026. The filing reported shared voting power over 3,381,606 shares and shared dispositive power over 3,751,558 shares and sole power over none, and it is, like the BlackRock filing, a passive ownership disclosure rather than a comment on the FDA path.

20 Red Flags to Monitor

Pipeline execution watch: reconcile the PVRL registry with the 2027 company initiation guidance; obtain updated ADX-248/ADX-246 timelines. Neither the old registry completion estimate nor past H1 2026 plans establish current readout dates. September 29 SEC presentation ClinicalTrials.gov NCT07402876

21 Bottom Line

As of September 29, $ALDX is a funded regulatory-appeal story with an unresolved efficacy dispute. The Type A and Type D meetings are completed historical steps. The next company-guided window is Q4 2026 for FDRR submission and an OND meeting, while the decision date remains unknown. A favourable appeal would improve the interpretation of the regulatory path, but the company’s own slides require a subsequent NDA resubmission. September 29 company release September 29 SEC presentation

The financial change is an extension of projected operating runway into 2029, not a new cash balance. The $45.1 million June 30 balance already incorporates the Hercules principal repayment. Lower first-half operating consumption is supportive of flexibility, but the current plan cannot be assumed to cover every possible new trial or development acceleration. AbbVie remains a conditional option; neither an option exercise nor an approval-linked payment is announced.

The pipeline also needs a revised reading. The latest company forecast places ADX-2191 PVRL Phase 3 initiation in 2027, while the older registry still says Recruiting. That discrepancy is disclosed rather than converted into a confirmed enrollment or readout catalyst. ADX-248/ADX-246 timelines are to be provided when available. Historical milestones remain background, not proof of execution.

The developments that would materially change this assessment are confirmation of FDRR submission, the OND response and its evidence requirements, a defined NDA resubmission/review path, updated financial disclosures and reconciliation of clinical execution with company guidance. Additional expert review, a denied appeal or substantial new evidence could increase uncertainty and cost. This analysis does not assign an approval probability, a price objective or a trading recommendation.